Precision BioSciences initiates first dosing in Phase 1/2 FUNCTION-DMD study
Precision BioSciences has dosed the first patient in the Phase 1/2 FUNCTION-DMD trial for DMD, marking a significant clinical development milestone for the company's ARCUS gene-editing platform.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day